SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development

Autor: Linda A. Lieberman, Nicholas Murgolo, Alex G. Therien, Gokul Swaminathan, Philip M. McKenna, Daniel J. Klein, Daria J. Hazuda, Bonnie J. Howell, David B. Olsen, Kenneth A. Koeplinger, Gregory C. Adam, Jessica A. Flynn
Rok vydání: 2021
Předmět:
RNA viruses
Viral Diseases
Lung Development
Pulmonology
Coronaviruses
Organogenesis
Review
Disease
Virus Replication
Bioinformatics
Biochemistry
Medical Conditions
0302 clinical medicine
Drug Discovery
Medicine
Biology (General)
Pathology and laboratory medicine
Furin
0303 health sciences
Respiratory distress
Drug discovery
Serine Endopeptidases
Proteases
Medical microbiology
Endocytosis
Enzymes
Drug repositioning
Infectious Diseases
Drug development
Viruses
SARS CoV 2
Pathogens
Viral Entry
SARS coronavirus
QH301-705.5
Immunology
Microbiology
Cell Line
Respiratory Disorders
03 medical and health sciences
Drug Development
Viral entry
Virology
Genetics
Humans
Molecular Biology
Tropism
030304 developmental biology
Medicine and health sciences
Biology and life sciences
SARS-CoV-2
business.industry
Organisms
Viral pathogens
Proteins
COVID-19
Covid 19
Virus Internalization
RC581-607
Cathepsins
Microbial pathogens
COVID-19 Drug Treatment
Viral Tropism
Respiratory Infections
Enzymology
Tissue tropism
Parasitology
Immunologic diseases. Allergy
business
Organism Development
Viral Transmission and Infection
030217 neurology & neurosurgery
Developmental Biology
Zdroj: PLoS Pathogens, Vol 17, Iss 2, p e1009225 (2021)
PLoS Pathogens
ISSN: 1553-7374
Popis: Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts.
Databáze: OpenAIRE
Externí odkaz: